Acute Myelogenous Leukemia (AML) is a common disease in people aged>60 years. About 50% of the patients are not eligible for aggressive chemotherapy (CT) and are only managed with conservative approaches. Results in this subset of patients have not been reported so far.
Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza di Roma, Ematologia, Ospedale S. Giovanni, Roma, Ematologia, Istituto Regina Elena, Roma, Italy. rob.lati@libero.it
